The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson??s disease

1998 ◽  
Vol 8 (6) ◽  
pp. 473???480 ◽  
Author(s):  
Palle Mark Christensen ◽  
Peter C. Gotzsche ◽  
Kim Br??sen
Keyword(s):  
Oxidation Polymorphism

scholarly journals Pharmcokinetics of imipramine and its four metabolites in relation to debrisoquine/sparteine type oxidation polymorphism

1992 ◽  
Vol 58 ◽  
pp. 78
Author(s):  
Eriko Koyama ◽  
Dong-Ryul Sohn ◽  
Sang-Goo Shin ◽  
Kan Chiba ◽  
Takashi Ishizaki
Keyword(s):  
Oxidation Polymorphism

The relationship between paroxetine and the sparteine oxidation polymorphism

1992 ◽  
Vol 51 (3) ◽  
pp. 278-287 ◽  
Author(s):  
Søren H Sindrup ◽  
Kim Brøsen ◽  
Lars F Gram ◽  
Jesper Hallas ◽  
Erik Skjelbo ◽  
...  
Keyword(s):  
Oxidation Polymorphism ◽  
The Relationship ◽  
Sparteine Oxidation

scholarly journals Timolol metabolism and debrisoquine oxidation polymorphism: a population study.

1989 ◽  
Vol 27 (4) ◽  
pp. 429-434 ◽  
Author(s):  
MS Lennard ◽  
RV Lewis ◽  
LA Brawn ◽  
GT Tucker ◽  
LE Ramsay ◽  
...  
Keyword(s):  
Population Study ◽  
Debrisoquine Oxidation ◽  
Oxidation Polymorphism

Debrisoquine oxidation polymorphism

1993 ◽  
Vol 3 (3) ◽  
pp. 123-130 ◽  
Author(s):  
F. Broly ◽  
U. A. Meyer
Keyword(s):  
Debrisoquine Oxidation ◽  
Oxidation Polymorphism

Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2

1998 ◽  
Vol 8 (1) ◽  
pp. 73-82 ◽  
Author(s):  
Yukio Yamamoto ◽  
Takafumi Tasaki ◽  
Akio Nakamura ◽  
Hisato Iwata ◽  
Akio Kazusaka ◽  
...  
Keyword(s):  
Molecular Basis ◽  
Dark Agouti ◽  
Drug Oxidation ◽  
Oxidation Polymorphism
Sign in / Sign up

Export Citation Format

Share Document